The TransCon Linker technology creates transient bonds between larger molecules such as proteins and peptides, including insulin, and a carrier.
Ascendis Pharma claims the TransCon Linker technology has shown promising results in preclinical studies in delivering insulin.
As per the terms of the agreement, Sanofi-aventis will receive a worldwide license to develop, manufacture and commercialize products combining the technology with active molecules in diabetes and related disorders.
Ascendis will receive an upfront payment and will be eligible to receive development, regulatory, and specified commercial milestone payments.
Sanofi-aventis Global Diabetes Division head and senior vice-president Pierre Chancel said they are excited about the promising technology to create next-generation products in the field of diabetes and related disorders.
"Building on our achievements with Lantus, our 24-hour insulin approved for use once a day, we hope to further improve the lives of people with diabetes by developing this innovative technology to offer biologicals that present an extended and controlled release of unmodified parent drugs, including insulin," Chancel said.
